solriamfetol — Topline data
Q4 2026
The Company anticipates topline results from the ENGAGE Phase 3 trial in the fourth quarter of 2026.Source filing
AXSM biotech catalysts & pipeline
AXSOME THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
solriamfetol — Topline data
2027
The Company anticipates topline results from the SUSTAIN Phase 3 trial in 2027.Source filing
reboxetine (AXS-12) — PDUFA
May 1
Narcolepsy: Axsome's NDA submission for AXS-12 for the treatment of cataplexy in narcolepsy was accepted by the FDA and assigned a PDUFA target action date of May 1, 2027.Source filing